Narrow therapeutic index drugs: A clinical pharmacological consideration to flecainide

European Journal of Clinical Pharmacology

Volumn 71, Issue 5, 2015, Pages 549-567

  Tamargo, Juan ^a   Le Heuzey, Jean Yves ^b   Mabo, Phillipe ^c  

^a SCHOOL OF MEDICINE   (Spain)

^b HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^c UNIVERSITÉ DE RENNES 1   (France)

Author keywords

Antiarrhythmic drugs; Bioequivalence; Flecainide; Generic drugs; Narrow therapeutic index; Safety

Indexed keywords

AMIODARONE; DISOPYRAMIDE; FLECAINIDE; GENERIC DRUG; PROCAINAMIDE; QUINIDINE; SOTALOL;

ANGINA PECTORIS; AREA UNDER THE CURVE; ARTICLE; ATRIOVENTRICULAR BLOCK; BIOEQUIVALENCE; BRADYCARDIA; CARDIAC PATIENT; CARDIOLOGIST; CARDIOVASCULAR EFFECT; CARDIOVASCULAR RISK; DIARRHEA; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG EFFICACY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MONITORING; DRUG RESPONSE; DRUG SAFETY; DRUG SUBSTITUTION; GENERAL PRACTITIONER; HEADACHE; HEART ARRHYTHMIA; HEART ATRIUM FLUTTER; HEART BUNDLE BRANCH BLOCK; HEART FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE ISCHEMIA; HEART MUSCLE OXYGEN CONSUMPTION; HEART PROARRHYTHMIA; HEART VENTRICLE EXTRASYSTOLE; HEMODYNAMICS; HUMAN; HYPOTENSION; INOTROPISM; LD50; LETHAL DOSE; MAXIMUM PLASMA CONCENTRATION; META ANALYSIS (TOPIC); METABOLIC CLEARANCE; MINIMUM EFFECTIVE CONCENTRATION; MINIMUM PLASMA CONCENTRATION; NAUSEA; PHARMACEUTICAL EQUIVALENCE; PHARMACODYNAMICS; PHARMACOLOGICAL PARAMETERS; PLASMA CONCENTRATION-TIME CURVE; PRACTICE GUIDELINE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); SINUS NODE RECOVERY TIME; SUPRAVENTRICULAR TACHYCARDIA; THERAPEUTIC EQUIVALENCE; THERAPEUTIC INDEX; TORSADE DES POINTES; TOXIC CONCENTRATION; VOLUME OF DISTRIBUTION; SAFETY;

DOSE-RESPONSE RELATIONSHIP, DRUG; DRUGS, GENERIC; FLECAINIDE; HUMANS; PRACTICE GUIDELINES AS TOPIC; SAFETY; THERAPEUTIC EQUIVALENCY;

EID: 84928523848     PISSN: 00316970     EISSN: 14321041     Source Type: Journal    
DOI: 10.1007/s00228-015-1832-0     Document Type: Article

References (137)

1. Katzung B, Masters S, Trevor A (2012) Basic and clinical pharmacology, 12th edn. Companies, Inc., New York
2. Reiffel JA (2000) Formulation substitution and other pharmacokinetic variability: underappreciated variables affecting antiarrhythmic efficacy and safety in clinical practice. Am J Cardiol 85:46D-52D
3. Reiffel JA (2001) Issues in the use of generic antiarrhythmic drugs. Curr Opin Cardiol 16:23-29
4. Buehler G (2010) History of bioequivalence for critical dose drugs
5. CFR - Code of Federal Register 21, section 320.33 (21CFR320.33) (2014) Criteria and evidence to assess actual or potential bioequivalence problems
6. Peters JR, Hixon DR, Conner DP et al (2009) Generic drugs - safe, effective, and affordable. Dermatol Ther 22:229-240. doi: 10.1111/j.1529-8019.2009.01236.x
7. US Department of Health and Human Services (2003) Guidance for industry. Bioavailability and bioequivalence studies for orally administered drug products - general considerations
8. US Department of Health and Human Services (2014) Approved drug products with therapeutic equivalence evaluations
9. Davit BM, Nwakama PE, Buehler GJ et al (2009) Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 43:1583-1597. doi: 10.1345/aph.1M141
10. Schuirmann DJ (1987) A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability. J Pharmacokinet Biopharm 15:657-680
11. Committee for Medicinal Products for Human Use (CHMP) (2010) Guideline on the investigation of bioequivalence
12. Hottinger M, Liang BA (2012) Deficiencies of the FDA in evaluating generic formulations: addressing narrow therapeutic index drugs. Am J Law Med 38:667-689
13. Meredith P (2003) Bioequivalence and other unresolved issues in generic drug substitution. Clin Ther 25:2875-2890
14. Wilkinson GR (2005) Drug metabolism and variability among patients in drug response. N Engl J Med 352:2211-2221. doi: 10.1056/NEJMra032424
15. Verbeeck RK, Musuamba FT (2012) The revised EMA guideline for the investigation of bioequivalence for immediate release oral formulations with systemic action. J Pharm Pharm Sci 15:376-388
16. Rocca B, Patrono C (2005) Determinants of the interindividual variability in response to antiplatelet drugs. J Thromb Haemost 3:1597-1602. doi: 10.1111/j.1538-7836.2005.01380.x
17. Vesell ES (1991) Genetic and environmental factors causing variation in drug response. Mutat Res 247:241-257
18. European Medicines Agency (EMA) (2014) Questions & answers: positions on specific questions addressed to the Pharmacokinetics Working Party, EMA/618604/2008 Rev. 10. Available from: http://www.ema.europa.eu/docs/en-GB/document-library/Scientific-guideline/2009/09/WC500002963.pdf.
19. Yu LX (2011) Approaches to demonstrate bioequivalence of narrow therapeutic index drugs
20. Yu LX (2011) Quality and bioequivalence standards for narrow therapeutic index drugs
21. US Food and Drug Administration (2010) Draft guidance on flecainide acetate
22. US Food and Drug Administration (2012) Center for Drug Evaluation and Research (CDER). Draft guidance on warfarin sodium. December 2012
23. US Food and Drug Administration (2012) Draft guidance on tacrolimus. December 2012
24. US Food and Drug Administration (2010) Summary minutes of the advisory committee for pharmaceutical science and clinical pharmacology. 13 April 2010
25. Zhang X, Zheng N, Lionberger RA, Yu LX (2013) Innovative approaches for demonstration of bioequivalence: the US FDA perspective. Ther Deliv 4:725-740. doi: 10.4155/tde.13.41
26. US Food and Drug Administration (2011) Center for Drug Evaluation and Research (CDER). Briefing information for the FDA Meeting of the Advisory Committee for Pharmaceutical Science and Clinical Pharmacology. Topic 1: bioequivalence (BE) and quality standards for narrow therapeutics index (NTI) drug products. 26 July 2011
27. Endrenyi L, Tothfalusi L (2013) Determination of bioequivalence for drugs with narrow therapeutic index: reduction of the regulatory burden. J Pharm Pharm Sci 16:676-682
28. Health Canada (2012) Guidance document - comparative bioavailability standards: formulations used for systemic effects. 22 May 2012. File number: 12-105972-31
29. New Zealand Medicines and Medical Devices Safety Authority New Zealand Regulatory Guidelines for Medicines. Part A: when is an application for approval of a new or changed medicine required?
30. New Zealand Regulatory Guidelines for Medicines (2014) Guideline on the regulation of therapeutic products in New Zealand. Part 6: bioequivalence of medicines. Edition 1.0
31. (2014) Therapeutic Goods Administration (TGA) of Australia
32. The Japanese Institute of Health Sciences (2012) Guideline for bioequivalence studies for different strengths of oral solid dosage forms
33. (2014) The Medicines Control Council (MCC) of South Africa
34. Danish Health and Medicines Authority (2012) Bioequivalence and labelling of medicinal products with regard to generic substitution
35. The Agence Fédérale des Médicaments et des Produits de Santé of Belgium (2011) Prescription en DCI
36. The Agence Fédérale des Médicaments et des Produits de Santé of Belgium (2012) Sécurité, efficacité et bioéquivalence
37. Agence Nationale de Sécurité des Médicaments (2014) Interactions médicamenteuses et cytochromes
38. La Agencia Española de Medicamentos y Productos Sanitarios Boletín Oficial del Estado. Núm 113 Sec. 1:35665
39. Camm AJ, Lip GYH, De Caterina R et al (2012) 2012 focused update of the ESC Guidelines for the management of atrial fibrillation: an update of the 2010 ESC Guidelines for the management of atrial fibrillation. Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J 33:2719-2747. doi: 10.1093/eurheartj/ehs253
40. Fuster V, Rydén LE, Cannom DS et al (2006) ACC/AHA/ESC 2006 guidelines for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to revise the 2001 guidelines for the management of patients with atrial fibrillation): developed in collaboration with the European Heart Rhythm Association and the Heart Rhythm Society. Circulation 114:e257-e354. doi: 10.1161/CIRCULATIONAHA.106.177292
41. Anderson JL, Halperin JL, Albert NM et al (2013) Management of patients with atrial fibrillation (compilation of 2006 ACCF/AHA/ESC and 2011 ACCF/AHA/HRS recommendations): a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. J Am Coll Cardiol 61:1935-1944. doi: 10.1016/j.jacc.2013.02.001
42. Holmes DR, Becker JA, Granger CB et al (2011) ACCF/AHA 2011 health policy statement on therapeutic interchange and substitution: a report of the American College of Cardiology Foundation Clinical Quality Committee. Circulation 124:1290-1310. doi: 10.1161/CIR.0b013e31822d97d5
43. Roden DM, Woosley RL (1986) Drug therapy. Flecainide. N Engl J Med 315:36-41. doi: 10.1056/NEJM198607033150106
44. Woosley RL, Siddoway LA, Duff HJ, Roden DM (1984) Flecainide dose-response relations in stable ventricular arrhythmias. Am J Cardiol 53:59B-65B
45. Tamargo J, Capucci A, Mabo P (2012) Safety of flecainide. Drug Saf 35:273-289. doi: 10.2165/11599950-000000000-00000
46. Aliot E, Capucci A, Crijns HJ et al (2011) Twenty-five years in the making: flecainide is safe and effective for the management of atrial fibrillation. Europace 13:161-173. doi: 10.1093/europace/euq382
47. Conard GJ, Ober RE (1984) Metabolism of flecainide. Am J Cardiol 53:41B-51B
48. Conard GJ, Cronheim GE, Klempt HW (1982) Relationship between plasma concentrations and suppression of ventricular extrasystoles by flecainide acetate (R-818), a new antiarrhythmic, in patients. Arzneimittelforschung 32:155-159
49. Duff HJ, Roden DM, Maffucci RJ et al (1981) Suppression of resistant ventricular arrhythmias by twice daily dosing with flecainide. Am J Cardiol 48:1133-1140
50. Hodges M, Haugland JM, Granrud G et al (1982) Suppression of ventricular ectopic depolarizations by flecainide acetate, a new antiarrhythmic agent. Circulation 65:879-885
51. Anderson JL, Stewart JR, Perry BA et al (1981) Oral flecainide acetate for the treatment of ventricular arrhythmias. N Engl J Med 305:473-477. doi: 10.1056/NEJM198108273050901
52. Kiblboeck D, Braeuer-Mocker M, Siostrzonek P, Reisinger J (2012) A misguided "pill in the pocket" approach with flecainide leading to cardiac arrest. BMJ Case Rep. doi: 10.1136/bcr-2012-006868
53. Anderson JL, Lutz JR, Allison SB (1983) Electrophysiologic and antiarrhythmic effects of oral flecainide in patients with inducible ventricular tachycardia. J Am Coll Cardiol 2:105-114
54. Morganroth J, Horowitz LN (1984) Flecainide: its proarrhythmic effect and expected changes on the surface electrocardiogram. Am J Cardiol 53:89B-94B
55. Holmes B, Heel RC (1985) Flecainide. A preliminary review of its pharmacodynamic properties and therapeutic efficacy. Drugs 29:1-33
56. Ting SM, Lee D, Maclean D, Sheerin NS (2008) Paranoid psychosis and myoclonus: flecainide toxicity in renal failure. Cardiology 111:83-86. doi: 10.1159/000119694
57. Salerno DM, Granrud G, Sharkey P et al (1986) Pharmacodynamics and side effects of flecainide acetate. Clin Pharmacol Ther 40:101-107
58. Homma M, Kuga K, Doki K et al (2005) Assessment of serum flecainide trough levels in patients with tachyarrhythmia. J Pharm Pharmacol 57:47-51. doi: 10.1211/0022357055128
59. Ranger S, Nattel S (1995) Determinants and mechanisms of flecainide-induced promotion of ventricular tachycardia in anesthetized dogs. Circulation 92:1300-1311
60. Nattel S (1998) Experimental evidence for proarrhythmic mechanisms of antiarrhythmic drugs. Cardiovasc Res 37:567-577
61. Coromilas J, Saltman AE, Waldecker B et al (1995) Electrophysiological effects of flecainide on anisotropic conduction and reentry in infarcted canine hearts. Circulation 91:2245-2263
62. Restivo M, Yin H, Caref EB et al (1995) Reentrant arrhythmias in the subacute infarction period. The proarrhythmic effect of flecainide acetate on functional reentrant circuits. Circulation 91:1236-1246
63. Echt DS, Liebson PR, Mitchell LB et al (1991) Mortality and morbidity in patients receiving encainide, flecainide, or placebo. The Cardiac Arrhythmia Suppression Trial. N Engl J Med 324:781-788. doi: 10.1056/NEJM199103213241201
64. Kennedy HL, Brooks MM, Barker AH et al (1994) Beta-blocker therapy in the Cardiac Arrhythmia Suppression Trial. CAST Investigators. Am J Cardiol 74:674-680
65. Muhiddin KA, Turner P, Blackett A (1985) Effect of flecainide on cardiac output. Clin Pharmacol Ther 37:260-263
66. Nathan AW, Hellestrand KJ, Bexton RS et al (1985) The proarrhythmic effects of flecainide. Drugs 29(Suppl 4):45-53
67. Amneal Pharmaceuticals (2013) Flecainide prescribing information
68. Meda Pharmaceuticals (2013) Flecainide acetate - summary of product characteristics (UK)
69. Estes NA, Garan H, Ruskin JN (1984) Electrophysiologic properties of flecainide acetate. Am J Cardiol 53:26B-29B
70. Anderson JL, Stewart JR, Crevey BJ (1984) A proposal for the clinical use of flecainide. Am J Cardiol 53:112B-119B
71. Hellestrand KJ, Bexton RS, Nathan AW et al (1982) Acute electrophysiological effects of flecainide acetate on cardiac conduction and refractoriness in man. Br Heart J 48:140-148
72. Boriani G, Diemberger I, Biffi M et al (2004) Pharmacological cardioversion of atrial fibrillation: current management and treatment options. Drugs 64:2741-2762
73. Falk RH (1992) Proarrhythmia in patients treated for atrial fibrillation or flutter. Ann Intern Med 117:141-150
74. Hellestrand KJ, Nathan AW, Bexton RS, Camm AJ (1984) Response of an abnormal sinus node to intravenous flecainide acetate. Pacing Clin Electrophysiol 7:436-439
75. Serruys PW, Vanhaleweyk G, Van Den Brand M et al (1983) The haemodynamic effect of intravenous flecainide acetate in patients with coronary artery disease. Br J Clin Pharmacol 16:51-59
76. De Paola AA, Horowitz LN, Morganroth J et al (1987) Influence of left ventricular dysfunction on flecainide therapy. J Am Coll Cardiol 9:163-168
77. Josephson MA, Kaul S, Hopkins J et al (1985) Hemodynamic effects of intravenous flecainide relative to the level of ventricular function in patients with coronary artery disease. Am Heart J 109:41-45
78. Cohen AA, Daru V, Covelli G et al (1985) Hemodynamic effects of intravenous flecainide in acute noncomplicated myocardial infarction. Am Heart J 110:1193-1196
79. Legrand V, Materne P, Vandormael M et al (1985) Comparative haemodynamic effects of intravenous flecainide in patients with and without heart failure and with and without beta-blocker therapy. Eur Heart J 6:664-671
80. + channel and drug-induced prolongation of the QRS complex. Br J Pharmacol 164:260-273. doi: 10.1111/j.1476-5381.2011.01415.x
81. Williams AJ, McQuinn RL, Walls J (1988) Pharmacokinetics of flecainide acetate in patients with severe renal impairment. Clin Pharmacol Ther 43:449-455
82. Braun J, Kollert JR, Becker JU (1987) Pharmacokinetics of flecainide in patients with mild and moderate renal failure compared with patients with normal renal function. Eur J Clin Pharmacol 31:711-714
83. Forland SC, Burgess E, Blair AD et al (1988) Oral flecainide pharmacokinetics in patients with impaired renal function. J Clin Pharmacol 28:259-267
84. Forland SC, Cutler RE, McQuinn RL et al (1988) Flecainide pharmacokinetics after multiple dosing in patients with impaired renal function. J Clin Pharmacol 28:727-735
85. Hohnloser SH, Zabel M (1992) Short- and long-term efficacy and safety of flecainide acetate for supraventricular arrhythmias. Am J Cardiol 70:3A-9A, discussion 9A-10A
86. Blix HS, Viktil KK, Moger TA, Reikvam A (2010) Drugs with narrow therapeutic index as indicators in the risk management of hospitalised patients. Pharm Pr Granada 8:50-55
87. Tennezé L, Tarral E, Ducloux N, Funck-Brentano C (2002) Pharmacokinetics and electrocardiographic effects of a new controlled-release form of flecainide acetate: comparison with the standard form and influence of the CYP2D6 polymorphism. Clin Pharmacol Ther 72:112-122. doi: 10.1067/mcp.2002.125946
88. Doki K, Homma M, Kuga K et al (2012) CYP2D6 genotype affects age-related decline in flecainide clearance: a population pharmacokinetic analysis. Pharmacogenet Genomics 22:777-783. doi: 10.1097/FPC.0b013e3283588fe5
89. Doki K, Homma M, Kuga K et al (2006) Effect of CYP2D6 genotype on flecainide pharmacokinetics in Japanese patients with supraventricular tachyarrhythmia. Eur J Clin Pharmacol 62:919-926. doi: 10.1007/s00228-006-0188-x
90. Doki K, Homma M, Kuga K et al (2009) Effects of CYP2D6 genotypes on age-related change of flecainide metabolism: involvement of CYP1A2-mediated metabolism. Br J Clin Pharmacol 68:89-96. doi: 10.1111/j.1365-2125.2009.03435.x
91. Funck-Brentano C, Becquemont L, Kroemer HK et al (1994) Variable disposition kinetics and electrocardiographic effects of flecainide during repeated dosing in humans: contribution of genetic factors, dose-dependent clearance, and interaction with amiodarone. Clin Pharmacol Ther 55:256-269
92. Mikus G, Gross AS, Beckmann J et al (1989) The influence of the sparteine/debrisoquin phenotype on the disposition of flecainide. Clin Pharmacol Ther 45:562-567
93. Lim KS, Cho J-Y, Jang I-J et al (2008) Pharmacokinetic interaction of flecainide and paroxetine in relation to the CYP2D6∗10 allele in healthy Korean subjects. Br J Clin Pharmacol 66:660-666. doi: 10.1111/j.1365-2125.2008.03267.x
94. Bertilsson L, Lou YQ, Du YL et al (1992) Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquin and S-mephenytoin. Clin Pharmacol Ther 51:388-397
95. Palmiere C, Lesta Mdel M, Sabatasso S et al (2012) Usefulness of postmortem biochemistry in forensic pathology: illustrative case reports. Leg Med Tokyo Jpn 14:27-35. doi: 10.1016/j.legalmed.2011.10.004
96. Tsao YY, Gugger JJ (2009) Delirium in a patient with toxic flecainide plasma concentrations: the role of a pharmacokinetic drug interaction with paroxetine. Ann Pharmacother 43:1366-1369. doi: 10.1345/aph.1M067
97. Pritchett EL, Wilkinson WE (1991) Mortality in patients treated with flecainide and encainide for supraventricular arrhythmias. Am J Cardiol 67:976-980
98. European Heart Rhythm Association, Heart Rhythm Society, Zipes DP et al (2006) ACC/AHA/ESC 2006 guidelines for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: a report of the American College of Cardiology/American Heart Association Task Force and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Develop Guidelines for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death). J Am Coll Cardiol 48:e247-e346. doi: 10.1016/j.jacc.2006.07.010
99. Wehling M (2002) Meta-analysis of flecainide safety in patients with supraventricular arrhythmias. Arzneimittelforschung 52:507-514. doi: 10.1055/s-0031-1299923
100. Aliot E, De Roy L, Capucci A et al (2003) Safety of a controlled-release flecainide acetate formulation in the prevention of paroxysmal atrial fibrillation in outpatients. Ann Cardiol Angeiol Paris 52:34-40
101. Andersen SS, Hansen ML, Gislason GH et al (2009) Antiarrhythmic therapy and risk of death in patients with atrial fibrillation: a nationwide study. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 11:886-891. doi: 10.1093/europace/eup119
102. Freemantle N, Lafuente-Lafuente C, Mitchell S et al (2011) Mixed treatment comparison of dronedarone, amiodarone, sotalol, flecainide, and propafenone, for the management of atrial fibrillation. Eur Eur Pacing Arrhythm Card Electrophysiol J Work Groups Card Pacing Arrhythm Card Cell Electrophysiol Eur Soc Cardiol 13:329-345. doi: 10.1093/europace/euq450
103. D'Alessandro LCA, Rieder MJ, Gloor J et al (2009) Life-threatening flecainide intoxication in a young child secondary to medication error. Ann Pharmacother 43:1522-1527. doi: 10.1345/aph.1L549
104. Khavandi A, Walker PR (2007) Flecainide cardiotoxicity precipitated by electrolyte imbalance. Caution with thiazide diuretics. Emerg Med J 24:e26. doi: 10.1136/emj.2006.044362
105. Taylor R, Gandhi MM, Lloyd G (2010) Tachycardia due to atrial flutter with rapid 1:1 conduction following treatment of atrial fibrillation with flecainide. BMJ 340:b4684
106. Friedman PL, Stevenson WG (1998) Proarrhythmia. Am J Cardiol 82:50N-58N
107. Naccarelli GV, Wolbrette DL, Luck JC (2001) Proarrhythmia. Med Clin North Am 85:503-526, xii
108. Almroth H, Andersson T, Fengsrud E et al (2011) The safety of flecainide treatment of atrial fibrillation: long-term incidence of sudden cardiac death and proarrhythmic events. J Intern Med 270:281-290. doi: 10.1111/j.1365-2796.2011.02395.x
109. Anderson JL, Gilbert EM, Alpert BL et al (1989) Prevention of symptomatic recurrences of paroxysmal atrial fibrillation in patients initially tolerating antiarrhythmic therapy. A multicenter, double-blind, crossover study of flecainide and placebo with transtelephonic monitoring. Flecainide Supraventricular Tachycardia Study Group. Circulation 80:1557-1570
110. Crijns HJ, Van Gelder IC, Van Gilst WH et al (1991) Serial antiarrhythmic drug treatment to maintain sinus rhythm after electrical cardioversion for chronic atrial fibrillation or atrial flutter. Am J Cardiol 68:335-341
111. Gulizia M, Mangiameli S, Orazi S et al (2008) A randomized comparison of amiodarone and class IC antiarrhythmic drugs to treat atrial fibrillation in patients paced for sinus node disease: the Prevention Investigation and Treatment: A Group for Observation and Research on Atrial arrhythmias (PITAGORA) trial. Am Heart J 155:100-107. doi: 10.1016/j.ahj.2007.08.033, 107.e1
112. Pietersen AH, Hellemann H (1991) Usefulness of flecainide for prevention of paroxysmal atrial fibrillation and flutter. Danish-Norwegian Flecainide Multicenter Study Group. Am J Cardiol 67:713-717
113. Sihm I, Hansen FA, Rasmussen J et al (1990) Flecainide acetate in atrial flutter and fibrillation. The arrhythmogenic effects. Eur Heart J 11:145-148
114. Van Wijk LM, den Heijer P, Crijns HJ et al (1989) Flecainide versus quinidine in the prevention of paroxysms of atrial fibrillation. J Cardiovasc Pharmacol 13:32-36
115. Aliot E, Denjoy I (1996) Comparison of the safety and efficacy of flecainide versus propafenone in hospital out-patients with symptomatic paroxysmal atrial fibrillation/flutter. The Flecainide AF French Study Group. Am J Cardiol 77:66A-71A
116. Carunchio A, Fera MS, Mazza A et al (1995) A comparison between flecainide and sotalol in the prevention of recurrences of paroxysmal atrial fibrillation. G Ital Cardiol 25:51-68
117. Chimienti M, Cullen MT, Casadei G (1995) Safety of flecainide versus propafenone for the long-term management of symptomatic paroxysmal supraventricular tachyarrhythmias. Report from the Flecainide and Propafenone Italian Study (FAPIS) Group. Eur Heart J 16:1943-1951
118. Naccarelli GV, Dorian P, Hohnloser SH, Coumel P (1996) Prospective comparison of flecainide versus quinidine for the treatment of paroxysmal atrial fibrillation/flutter. The Flecainide Multicenter Atrial Fibrillation Study Group. Am J Cardiol 77:53A-59A
119. Steinbeck G, Doliwa R, Bach P (1988) [Therapy of paroxysmal atrial fibrillation. Cardiac glycosides alone or combined with anti-arrhythmia agents?]. Dtsch Med Wochenschr 113:1867-1871. doi: 10.1055/s-2008-1067903
120. Van Gelder IC, Crijns HJ, Van Gilst WH et al (1989) Efficacy and safety of flecainide acetate in the maintenance of sinus rhythm after electrical cardioversion of chronic atrial fibrillation or atrial flutter. Am J Cardiol 64:1317-1321
121. Lafuente-Lafuente C, Longas-Tejero MA, Bergmann J-F, Belmin J (2012) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev 5:CD005049. doi: 10.1002/14651858.CD005049.pub3
122. Lafuente-Lafuente C, Mouly S, Longas-Tejero MA, Bergmann JF (2007) Antiarrhythmics for maintaining sinus rhythm after cardioversion of atrial fibrillation. Cochrane Database Syst Rev CD005049. doi: 10.1002/14651858.CD005049.pub2
123. McNamara RL, Tamariz LJ, Segal JB, Bass EB (2003) Management of atrial fibrillation: review of the evidence for the role of pharmacologic therapy, electrical cardioversion, and echocardiography. Ann Intern Med 139:1018-1033
124. Balthasar JP (1999) Bioequivalence and bioequivalency testing. Am J Pharm Educ 63:194-198
125. Beyth RJ, Shorr RI (2002) Principles of drug therapy in older patients: rational drug prescribing. Clin Geriatr Med 18:577-592
126. Kasmer RJ, Nara AR, Green JA et al (1987) Comparable steady-state bioavailability between two preparations of conventional-release procainamide hydrochloride. Drug Intell Clin Pharm 21:183-186
127. Hilleman DE, Patterson AJ, Mohiuddin SM et al (1988) Comparative bioequivalence and efficacy of two sustained-release procainamide formulations in patients with cardiac arrhythmias. Drug Intell Clin Pharm 22:554-558
128. Grubb BP (1989) Recurrence of ventricular tachycardia after conversion from proprietary to generic procainamide. Am J Cardiol 63:1532-1533
129. Ozahowski T, Greenburg M, Mock R (1998) Clinical inequivalence of generic and brand name type IA antiarrhythmic drugs. PACE 21:809
130. Hendeles L, Hochhaus G, Kazerounian S (1993) Generic and alternative brand-name pharmaceutical equivalents: select with caution. Am J Hosp Pharm 50:323-329
131. Parker RE, Martinez DR, Covington TR (1991) Drug product selection - part 3: the orange book. Am Pharm 31:47-56
132. Food and Drug Administration, Center for Drugs and Biologics (1993) Approved drug products with therapeutic equivalence evaluations, 13th edn
133. Kahan BD (1999) Considerations concerning generic formulations of immunosuppressive drugs. Transplant Proc 31:1635-1641
134. Reiffel JA, Kowey PR (2000) Generic antiarrhythmics are not therapeutically equivalent for the treatment of tachyarrhythmias. Am J Cardiol 85:1151-1153, A10
135. Coumel P, Maison-Blanche P, Tarral E et al (2003) Pharmacodynamic equivalence of two flecainide acetate formulations in patients with paroxysmal atrial fibrillation by QRS analysis of ambulatory electrocardiogram. J Cardiovasc Pharmacol 41:771-779
136. American Medical Association (2004) Report 2 of the Council on Science and Public Health (A-04). Impact of drug formularies and therapeutic interchange on health outcomes
137. Köppel C, Oberdisse U, Heinemeyer G (1990) Clinical course and outcome in class IC antiarrhythmic overdose. J Toxicol Clin Toxicol 28:433-444